Seattle Genetics Inc (NASDAQ:SGEN)

36.22
Delayed Data
As of Mar 27
 +0.50 / +1.40%
Today’s Change
30.05
Today|||52-Week Range
47.67
+12.73%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.5B

Company Description

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell in 1998 and is headquartered in Bothell, WA.

Contact Information

Seattle Genetics, Inc.
21823 30th Drive SE
Bothell Washington 98021
P:(425) 527-4000
Investor Relations:
(425) 527-4160

Employees

Shareholders

Other institutional53.24%
Mutual fund holders52.23%
Individual stakeholders34.42%

Top Executives

Clay B. SiegallChairman, President & Chief Executive Officer
Eric L. DobmeierChief Operating Officer
Todd E. SimpsonChief Financial Officer
Jonathan DrachmanChief Medical Officer, EVP-Research & Development
Eric SieversSenior Vice President-Clinical Development

To view my watchlist

Not a member yet?

Sign up now for a free account